Human recombinant extracellular-superoxide dismutase type C improves cardioplegic protection against ischemia/reperfusion injury in isolated rat heart.
The cardioprotective effects of human recombinant extracellular-superoxide dismutase type C (hr-EC-SOD C) were compared with those of bovine Cu,Zn-SOD in isolated working rat heart subjected to 35-min global normothermic ischemia followed by 55-min reperfusion. hr-EC-SOD C or bovine Cu,Zn-SOD (3 x 10(4) and 6 x 10(4) IU/L, respectively) was added to St. Thomas' Hospital (STH) cardioplegic solution infused 5 min before and 10 min after the ischemic period. Control hearts were treated with STH cardioplegic solution without SOD. By the end of reperfusion, hr-EC-SOD C-treated hearts recovered left ventricular systolic pressure (LVSP), aortic flow (AF) and cardiac output (CO) to 95 +/- 4, 60 +/- 4, 69 +/- 6% of preischemic value, respectively, as compared with 86 +/- 3, 44 +/- 5, and 52 +/- 6% in the control (p < 0.05). Cardioplegia with hr-EC-SOD C significantly reduced lactate dehydrogenase (LDH) release into myocardial effluent during reperfusion (p < 0.05) and increased ATP, AMP, and total creatine (Cr) tissue contents in reperfused hearts (by 21 +/- 3, 42 +/- 4, and 34 +/- 3%, respectively, as compared with control hearts, p < 0.05). The effects of bovine SOD on functional and biochemical indexes were similar but not statistically significant as compared with control. Treatment with hr-EC-SOD C, but not with bovine SOD, resulted in reduction in hydroxyl radical formation assessed by 5-5-dimethy-1-pyrroline-N-oxide spin trap (DMPO) in coronary effluent at early reperfusion with electron spin resonance (ESR) technique. The results suggest that enhanced myocardial protection against ischemia/reperfusion injury afforded by hr-EC-SOD C is related to scavenging of oxygen-derived free radicals.
Pisarenko
O I
OI
Institute of Experimental Cardiology, Academy of Medical Sciences, Moscow, Russia.
Studneva
I M
IM
Lakomkin
V L
VL
Timoshin
A A
AA
Kapelko
V I
VI
D000818:Animals; D001639:Bicarbonates / Q000627:therapeutic use; D002122:Calcium Chloride / Q000627:therapeutic use; D002417:Cattle; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007511:Ischemia / Q000201:enzymology / Q000628:therapy*; D007527:Isoenzymes / Q000627:therapeutic use; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008274:Magnesium / Q000627:therapeutic use; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000628:therapy*; D011189:Potassium Chloride / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012965:Sodium Chloride / Q000627:therapeutic use; D013482:Superoxide Dismutase / Q000627:therapeutic use*
D001639:Bicarbonates; D007527:Isoenzymes; C041711:St. Thomas' Hospital cardioplegic solution; D012965:Sodium Chloride; D011189:Potassium Chloride; D007770:L-Lactate Dehydrogenase; D013482:Superoxide Dismutase; D008274:Magnesium; D002122:Calcium Chloride